Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

mogamulizumab 7Specimen Handling 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5Biopsy 5pembrolizumab 4fludarabine 4Magnetic Resonance Spectroscopy 4Brentuximab Vedotin 4hypericin 3fludarabine phosphate 3cemiplimab 3Radiotherapy 3Nivolumab 3sodium-iodide symporter 2X-Rays 2Whole-Body Irradiation 2Tacrolimus 2Phototherapy 2Photons 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Busulfan 2talimogene laherparepvec 1ruxolitinib 1romidepsin 1magrolimab 1duvelisib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × Lactones × 1 year × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡